Survey and analysis of studies on off-label use in China

Zhan-miao YI,Xiao-xiao LI,Jun-wen ZHOU,Ying-ying YAN,Suo-di ZHAI
DOI: https://doi.org/10.3969/j.issn.1672-3384.2015.01.013
2015-01-01
Abstract:Objective:To investigate the current situation of studies on off-label use in China.Methods:PubMed, CNKI, SinoMed and WanFang Data were searched through to April 2014 for observational studies on off-label use. Study characteristics and outcomes were extracted and analyzed.Results: In total, 39 studies were included. China began to publish studies on off-label use since 2008, and the ifrst English paper was reported in 2011. The authors involving in 33 institutions were mainly from Beijing, Sichuan and Guangdong provinces. The totally frequency of citation added up to 97 while download times were 4 679. The proportion of studies published by pharmacists reached 79.49%. As for the main contents, 36 reports (92.31%) belonged to single-center studies, and 34 (87.18%) reports focused on prescriptions or doctor's advice. Furthermore, there are 14 papers (35.90%) posted pediatric drugs, and 37 papers (94.87%) referred drug directions approved by CFDA as eligibility criteria to determine whether it was off-label use or not.Conclusion: Though studies on off-label use have been developing rapidly in China, there are still tremendous limitations in such aspects as researchers, types of studies, study focus and drug classes, as well as standard eligibility criteria for off-label use.
What problem does this paper attempt to address?